Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 85

Results For "Pharma"

4738 News Found

CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals
News | July 05, 2023

CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals

The 'A+' rating reflects IOL's robust business model, diversified product portfolio


Solara Active Pharma approves rights issue of Rs. 450 Cr
News | July 05, 2023

Solara Active Pharma approves rights issue of Rs. 450 Cr

The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.


BDR Pharma's Nilotinib sets a new standard in the treatment of Philadelphia Chromosome-positive leukaemia
News | July 05, 2023

BDR Pharma's Nilotinib sets a new standard in the treatment of Philadelphia Chromosome-positive leukaemia

Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases


Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules
News | July 04, 2023

Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules

The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models


Adare Pharma divests Adare Biome to dsm-firmenich
News | July 04, 2023

Adare Pharma divests Adare Biome to dsm-firmenich

The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x


Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24
Drug Approval | July 03, 2023

Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24

Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.


Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide shows nearly 19% weight loss in people with obesity
News | June 28, 2023

Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide shows nearly 19% weight loss in people with obesity

Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite


Ashland announces Polyplasdone Plus multifunctional disintegrant for improved pharmaceutical process
News | June 26, 2023

Ashland announces Polyplasdone Plus multifunctional disintegrant for improved pharmaceutical process

This innovative product eliminates two manufacturing steps and simplifies equipment setup


Sun Pharma presents data from Phase 1 studies of GL0034
News | June 26, 2023

Sun Pharma presents data from Phase 1 studies of GL0034

GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity